Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.

New research suggests Covid-19 mRNA vaccines offer benefits beyond viral protection. These vaccines may boost the immune ...

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...

MODERNA said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed to meet the main goal of a late-stage ...

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

Moderna’s highly touted cytomegalovirus vaccine — long billed as its next big win after its Covid-19 shot — failed a Phase 3 ...